FREHEMGO DIN 02572109
Status: Approved
Holder: NOVO NORDISK CANADA INC
Health Canada record
| Active ingredient(s) | DENECIMIG 4 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | B02BX OTHER SYSTEMIC HEMOSTATICS |
|---|
| Original market date | |
|---|
| Current status date | 02-Oct-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Novo Nordisk Canada Inc — licence 100175, currently licensed, last inspection rating C (2023-02-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DENECIMIG
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02572095 | FREHEMGO | NOVO NORDISK CANADA INC | Solution | DENECIMIG 1.6 MG | Approved |
| 02572125 | FREHEMGO | NOVO NORDISK CANADA INC | Solution | DENECIMIG 20 MG | Approved |
| 02572117 | FREHEMGO | NOVO NORDISK CANADA INC | Solution | DENECIMIG 9 MG | Approved |
| 02572133 | FREHEMGO | NOVO NORDISK CANADA INC | Solution | DENECIMIG 46 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 38420 | 2026-10-02 | New Drug Submission (NDS) | |
Request a quote for FREHEMGO
How to read a Canadian DIN record